TRT and Sleep Apnea: Risks, Evidence, and How to Manage Both Safely

How Testosterone and Sleep Apnea Are Connected

Low testosterone and obstructive sleep apnea share a bidirectional relationship. Each condition worsens the other, creating a cycle that can be difficult to break without addressing both problems simultaneously.

OSA is common. The American Academy of Sleep Medicine estimates that roughly 34% of men between ages 30 and 70 meet diagnostic criteria for at least mild OSA [1]. Among men with moderate-to-severe OSA (apnea-hypopnea index, or AHI, of 15 or higher), prevalence of biochemical hypogonadism ranges from 35% to 50% [2]. The connection is not coincidental. Fragmented sleep suppresses pulsatile gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus. Because testosterone production peaks during deep sleep, repeated apneic arousals blunt nocturnal testosterone surges [3]. A cross-sectional analysis published in the Journal of Clinical Endocrinology & Metabolism found that each additional 10-unit increase in AHI was associated with a 19 ng/dL decrease in total testosterone [4].

The reverse pathway matters too. Exogenous testosterone may increase upper-airway collapsibility by promoting fat deposition in pharyngeal tissues and altering neuromuscular tone in the genioglossus muscle [5]. Small interventional studies from the early 2000s showed that supraphysiologic testosterone doses worsened AHI in healthy older men, though physiologic replacement doses produced inconsistent effects [6].

What the Endocrine Society Guidelines Recommend

The 2018 Endocrine Society Clinical Practice Guideline on testosterone therapy states clearly: clinicians should not initiate TRT in men with untreated severe OSA [7]. This is a strong recommendation.

The guideline also advises clinicians to evaluate all TRT candidates for OSA symptoms using validated questionnaires such as the STOP-BANG score before prescribing testosterone [7]. A STOP-BANG score of 5 or higher indicates high probability of moderate-to-severe OSA and warrants a formal polysomnography or home sleep apnea test before TRT begins.

For men with mild-to-moderate OSA already on CPAP, the guidelines permit TRT initiation with close follow-up. The AUA (American Urological Association) 2018 guideline echoes this position, recommending that OSA be treated and stabilized before testosterone therapy starts [8]. Neither society considers well-controlled OSA an absolute contraindication.

Can CPAP Therapy Raise Testosterone on Its Own?

Treating OSA with continuous positive airway pressure (CPAP) may partially restore endogenous testosterone production, reducing or eliminating the need for TRT in some men.

A randomized controlled trial by Meston and colleagues (N=101) found that three months of CPAP use increased morning total testosterone by an average of 55 ng/dL in men with severe OSA, compared to sham CPAP [9]. The effect was most pronounced in younger men (under 50) with a baseline AHI above 30. A separate meta-analysis of 10 studies (N=591) published in Sleep Medicine Reviews concluded that effective CPAP therapy produced a statistically significant, though modest, increase in serum testosterone: a pooled mean difference of approximately 44 ng/dL [10].

These gains may not be sufficient for all patients. Men whose total testosterone remains below 264 ng/dL after 3 to 6 months of compliant CPAP use (defined as 4 or more hours per night on 70% of nights) are reasonable candidates for concurrent TRT, provided their AHI has normalized on treatment [7].

How TRT May Worsen Sleep Apnea: The Mechanisms

Three pathways explain how exogenous testosterone could aggravate OSA.

Central respiratory drive. Testosterone modulates the hypoxic ventilatory response. An early crossover trial by Matsumoto and colleagues gave healthy men intramuscular testosterone enanthate 200 mg weekly for six weeks and observed a significant increase in apneic events during sleep [6]. The proposed mechanism involves altered CO2 chemosensitivity at the level of the carotid body and brainstem respiratory centers [11].

Upper-airway anatomy. Testosterone promotes regional adiposity in the submandibular and parapharyngeal fat pads, narrowing the retropalatal airway [5]. This effect is dose-dependent and more clinically relevant in men who are already overweight.

Fluid redistribution. Testosterone increases extracellular fluid volume. During recumbency, rostral fluid shift from the legs to the neck increases pharyngeal tissue pressure, a mechanism well-described in the OSA literature independent of testosterone [12]. TRT may amplify this effect.

Not every man on TRT develops worsening apnea. A 2019 systematic review in Sleep and Breathing concluded that the risk is highest among men with BMI above 30, neck circumference above 17 inches, and pre-existing but undiagnosed OSA [13].

Erythrocytosis and Hematocrit: The Compounding Risk

Erythrocytosis (elevated red blood cell mass) is the most common laboratory side effect of TRT. The Endocrine Society guideline identifies a hematocrit above 54% as a threshold requiring dose reduction or treatment cessation [7]. OSA independently stimulates erythropoietin (EPO) production through chronic intermittent hypoxia [14].

When a man has both untreated OSA and TRT, these two erythropoietic stimuli are additive. A retrospective cohort study published in Clinical Endocrinology (N=231) found that men on TRT with concurrent untreated OSA had a 3.2-fold higher risk of developing hematocrit above 54% compared with TRT users without OSA [15]. Monitoring hematocrit at baseline, 3 months, 6 months, and annually thereafter is standard of care [7].

If hematocrit exceeds 54%, first-line management includes reducing the testosterone dose, switching from intramuscular injections (which produce higher peak levels) to transdermal formulations, and ensuring CPAP compliance. Therapeutic phlebotomy is a short-term option but does not address the underlying cause [16].

TRT and Prostate Health: What the Data Actually Show

The historical concern that testosterone fuels prostate cancer originated from Huggins and Hodges' 1941 observation that castration caused prostate tumor regression. For decades, clinicians extrapolated that adding testosterone would cause prostate cancer growth. Modern evidence does not support this linear assumption.

The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, is the largest randomized controlled trial of TRT to date. Over a median follow-up of 33 months, testosterone-treated men showed no statistically significant increase in prostate cancer incidence compared with placebo (0.19 vs. 0.15 events per 100 person-years; HR 1.07 to 95% CI 0.50 to 2.28) [17]. The Endocrine Society notes that TRT is contraindicated in men with metastatic prostate cancer or locally advanced disease but not in men with a history of low-grade, treated prostate cancer after appropriate oncologic clearance [7].

Regarding benign prostatic hyperplasia (BPH), a meta-analysis of 26 RCTs (N=3,834) found no significant difference in International Prostate Symptom Score (IPSS) changes between TRT and placebo groups over 6 to 36 months [18]. PSA increases on TRT are typically modest (0.3 to 0.5 ng/mL in the first 12 months) and stabilize thereafter [7].

How to Screen for OSA Before Starting TRT

A structured pre-TRT workup for OSA takes about 15 minutes and can prevent serious complications.

Step 1: STOP-BANG questionnaire. This validated eight-item screen assigns one point each for: Snoring, Tiredness, Observed apneas, high blood Pressure, BMI above 35, Age above 50, Neck circumference above 16 inches, and male Gender [19]. A score of 0 to 2 is low risk. A score of 3 to 4 is intermediate. Five or higher is high risk.

Step 2: Epworth Sleepiness Scale. This 8-item self-report measures daytime sleepiness on a scale of 0 to 24. A score above 10 suggests excessive daytime sleepiness consistent with untreated sleep-disordered breathing [20].

Step 3: Home sleep apnea test (HSAT) or polysomnography. For intermediate-to-high-risk patients, an HSAT provides AHI data sufficient for most diagnostic purposes. Polysomnography remains the gold standard when HSAT results are inconclusive or when central sleep apnea is suspected [1].

Any man with an AHI of 15 or higher should start CPAP (or an appropriate alternative such as a mandibular advancement device) before testosterone initiation. Reassessment of AHI after 30 to 90 days of PAP therapy confirms adequate control before adding TRT.

Monitoring OSA Symptoms During TRT

Starting TRT does not end the conversation about sleep apnea. Ongoing surveillance catches new-onset or worsening OSA early.

At each follow-up visit (3 months, 6 months, 12 months, then annually), clinicians should reassess snoring severity, witnessed apneas, daytime sleepiness (repeat Epworth Sleepiness Scale), and partner reports [7]. Any increase in Epworth score by 3 or more points warrants a repeat sleep study. Weight gain during TRT, while uncommon, may independently worsen AHI and should prompt re-evaluation.

Dr. Bradley Anawalt, an endocrinologist at the University of Washington and co-author of the Endocrine Society guideline, has stated: "The risk of TRT worsening sleep apnea is real but manageable. The key is not to avoid testosterone therapy entirely. It is to diagnose and treat sleep apnea first" [7].

Dr. Ronald Swerdloff, chief of the division of endocrinology at Harbor-UCLA Medical Center, noted during the Testosterone Trials (TTrials) analysis: "Men who had adequate CPAP therapy and then received testosterone did not show worsening of their sleep-disordered breathing, which supports concurrent treatment when OSA is controlled" [21].

Other TRT Side Effects Worth Knowing

Sleep apnea is one piece of a broader side-effect profile. A complete informed-consent discussion should also address:

Erythrocytosis. As discussed, the most common lab abnormality. Frequency ranges from 5% to 18% depending on the formulation and dosing interval [7].

Acne and oily skin. Occurs in roughly 15% to 20% of TRT users, more common with injectable formulations that produce supraphysiologic peaks [17].

Testicular atrophy and infertility. Exogenous testosterone suppresses intratesticular testosterone production and spermatogenesis via negative feedback on LH and FSH. Men desiring fertility should discuss alternatives such as enclomiphene or hCG co-administration [8].

Cardiovascular events. The TRAVERSE trial showed a higher incidence of non-fatal arrhythmias (atrial fibrillation) in the testosterone group but no increase in major adverse cardiovascular events (MACE) over 33 months (HR 0.96 to 95% CI 0.78 to 1.17) [17].

Gynecomastia. Aromatization of testosterone to estradiol may cause breast tissue enlargement in 5% to 10% of men on TRT, particularly those with higher body fat percentages [7].

Practical Recommendations for Men Considering TRT

For men with symptoms of both low testosterone and possible OSA, a clear clinical sequence reduces risk.

Get a sleep study before your first testosterone prescription. A STOP-BANG score of 3 or above, daytime fatigue, or a bed partner reporting snoring or gasping warrants formal testing [19]. If OSA is confirmed, start PAP therapy and give it 30 to 90 days to assess compliance and effectiveness. Recheck morning total testosterone after consistent CPAP use, as levels may improve enough to defer TRT. If testosterone remains below 264 ng/dL with a repeat confirmatory sample, initiate TRT at standard physiologic doses (testosterone cypionate 100 to 200 mg intramuscularly every 7 to 14 days, or transdermal gel 50 mg daily) [7]. Monitor hematocrit at baseline, 3 months, and 6 months, then annually. Recheck PSA at 3 to 6 months and 12 months [7]. Report new or worsening snoring, witnessed apneas, or daytime sleepiness at every follow-up visit. Men with a hematocrit rising above 50% while on TRT with concurrent OSA should have their CPAP data reviewed, testosterone dose reduced, and a repeat CBC drawn within 4 to 6 weeks [15].